Xiidra
(Lifitegrast)ApprovedSmall molecule
Xiidra is one of 72 small molecule programs targeting Cataract. It is currently in Approved.
3
Indications
18
Total Trials
1
Active Trials
71
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
11
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Cataract
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Eylea
RegeneronApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Toradol
RocheApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levaquin
WWim Janssens
Approved
Cipro
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eye Disease4 trials
Efficacy3 trials
Dry Eye Disease2 trials
Allergic Conjunctivitis1 trial
7 more indications
Efficacy and Safety1 trial
Prospective1 trial
Safety and Efficacy1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jul 11, 2016
XIIDRA
NDA NDA208073
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lifitegrast. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Xiidra. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.